<DOC>
	<DOCNO>NCT03011177</DOCNO>
	<brief_summary>To assess efficacy safety Teneligliptin Linagliptin type 2 DM patient .</brief_summary>
	<brief_title>Teneligliptin Versus Linagliptin Diabetes Mellitus Type Two Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Patients 19 year old screen Patients type 2 diabetes mellitus Patients 7.0 % ≤ HbA1c ≤ 11.0 % screen visit Patients FPG &lt; 15mmol/L ( 270mg/dL ) screening</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>